Skip to main content
. 2015 Dec 10;112(52):16018–16023. doi: 10.1073/pnas.1522150112

Fig. 3.

Fig. 3.

Rapid effects of 17β-estradiol and estrogen receptor agonists on CA1 pyramidal neuron mEPSCs. (A) Location of patched neurons corresponds to location of bilateral cannulas in behavioral experiments. (B) Schematic of treatment protocols. (C and D) Percent baseline of mEPSC frequency and amplitude; mean ± SEM. (C) Fifteen to 20 min of 50 nM 17β-estradiol or 100 nM ERα agonist PPT reduces CA1 mEPSC frequency (Estradiol: F3, 35 = 3.18, P < 0.05; post hoc q = 4.20, df = 18, P < 0.05; PPT: F3, 40 = 5.72, P < 0.01; post hoc q = 3.93, df = 20, P < 0.05). ERβ agonist DPN does not affect mEPSC frequency. (D) Treatments do not affect mEPSC amplitude. (E) Five-minute mEPSC traces of baseline (Left) and traces after 15–20 min of vehicle, 50 nM 17β-estradiol, 100 nM PPT, or 100nM DPN application (Right). White and colored boxes indicate the presence of vehicle or hormones during the recording. (F) Total number of mEPSCs for all neurons recorded within a treatment group. 17β-Estradiol and PPT appear to decrease mEPSCs across all amplitudes fairly equally. *P < 0.05.